A clinical study of TCRT-ESO-A2 for solid tumours
Latest Information Update: 29 Sep 2020
At a glance
- Drugs TCRT-ESO-A2 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 29 Sep 2020 New trial record
- 23 Sep 2020 According to an Athenex media release, the USA Food and Drug Administration (FDA) has allowed an Investigational New Drug (IND) application for TCRT-ESO-A2 targeting solid tumors.